Heart Failure : The most important, preventable, and treatable cardiovascular complication of type 2 diabetes

Diabetes Care

Volumn 41, Issue 1, 2018, Pages 11-13

  Packer, Milton ^a  

^a BAYLOR UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ALOGLIPTIN; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; EMPAGLIFLOZIN; EPLERENONE; GLUCOSE; LIRAGLUTIDE; METFORMIN; SACUBITRIL; SAXAGLIPTIN; SPIRONOLACTONE; SULFONYLUREA DERIVATIVE; VALSARTAN;

CARDIOVASCULAR MORTALITY; CARDIOVASCULAR RISK; DISEASE SEVERITY; DRUG EFFICACY; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HEART FAILURE; HEART FAILURE WITH PRESERVED EJECTION FRACTION; HEART MUSCLE ISCHEMIA; HEART VENTRICLE FUNCTION; HUMAN; HYPERGLYCEMIA; HYPERINSULINEMIA; HYPOGLYCEMIA; INSULIN RESISTANCE; MORBIDITY; NON INSULIN DEPENDENT DIABETES MELLITUS; NOTE; PREVALENCE; RISK REDUCTION; SIGNAL TRANSDUCTION; SUDDEN DEATH; HOSPITALIZATION;

DIABETES MELLITUS, TYPE 2; HEART FAILURE; HOSPITALIZATION; HUMANS;

EID: 85038966600     PISSN: 01495992     EISSN: 19355548     Source Type: Journal    
DOI: 10.2337/dci17-0052     Document Type: Note

References (25)

1. McMurray JJ, Gerstein HC, Holman RR, Pfeffer MA. Heart failure: a cardiovascular outcome in diabetes that can no longer be ignored. Lancet Diabetes Endocrinol 2014; 2: 843-851
2. Desai AS, McMurray JJ, Packer M, et al. Effect of the angiotensin-receptor-neprilysin inhibitor LCZ696 compared with enalapril on mode of death in heart failure patients. Eur Heart J 2015; 36: 1990-1997
3. Packer M. Activation, and inhibition of sodiumhydrogen exchanger is a mechanismthat links the pathophysiology, and treatment of diabetes mellitus with that of heart failure. Circulation 2017; 136: 1548-1559
4. Van Den Berge JC, Constantinescu AA, Boiten HJ, van Domburg RT, Deckers JW, Akkerhuis KM. Short-and long-term prognosis of patients with acute heart failure with, and without diabetes: changes over the last three decades. Diabetes Care 2018; 41: 143-149
5. Sandesara PB, O'Neal WT, Kelli HM, et al. The prognostic significance of diabetes, and microvascular complications in patients with heart failure with preserved ejection fraction. Diabetes Care 2018; 41: 150-155
6. Castagno D, Baird-Gunning J, Jhund PS, et al. Intensive glycemic control has no impact on the risk of heart failure in type 2 diabetic patients: evidence from a 37,229 patient meta-analysis. Am Heart J 2011; 162: 938-948.e2
7. Nichols GA, Koro CE, Gullion CM, Ephross SA, Brown JB. The incidence of congestive heart failure associated with antidiabetic therapies. Diabetes Metab Res Rev 2005; 21: 51-57
8. Margulies KB, Hernandez AF, Redfield MM, et al. NHLBI Heart Failure Clinical Research Network. Effects of liraglutide on clinical stability among patients with advanced heart failure, and reduced ejection fraction: a randomized clinical trial. JAMA 2016; 316: 500-508
9. Jorsal A, Kistorp C, Holmager P, et al. Effect of liraglutide, a glucagon-like peptide-1 analogue, on left ventricular function in stable chronic heart failure patients with, and without diabetes (LIVE)da multicentre, double-blind, randomised, placebocontrolled trial. Eur J Heart Fail 2017; 19: 69-77
10. U.S. Food, and Drug Administration. Diabetes medications containing saxagliptin, and alogliptin: drug safety communication -risk of heart failure [Internet], 2016. Available from https://www.fda.gov/safety/medwatch/safetyinformation/safetyalertsforhumanmedicalproducts/ucm494252.htm. Accessed 4 October 2017
11. Varas-Lorenzo C, Margulis AV, Pladevall M, et al. The risk of heart failure associated with the use of noninsulin blood glucose-lowering drugs: systematic review, and meta-analysis of published observational studies. BMC Cardiovasc Disord 2014; 14: 129
12. Zinman B, Wanner C, Lachin JM, et al. EMPAREG OUTCOME Investigators. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med 2015; 373: 2117-2128
13. Eurich DT, Weir DL, Majumdar SR, et al. Comparative safety, and effectiveness of metformin in patients with diabetes mellitus, and heart failure: systematic review of observational studies involving 34,000 patients. Circ Heart Fail 2013; 6: 395-402
14. Shimizu I, Minamino T, Toko H, et al. Excessive cardiac insulin signaling exacerbates systolic dysfunction induced by pressure overload in rodents. J Clin Invest 2010; 120: 1506-1514
15. Arnold JM, Yusuf S, Young J, et al. HOPE Investigators. Prevention of heart failure in patients in the Heart Outcomes Prevention Evaluation (HOPE) study. Circulation 2003; 107: 1284-1290
16. Rydén L, Armstrong PW, Cleland JG, et al. Efficacy, and safety of high-dose lisinopril in chronic heart failure patients at high cardiovascular risk, including those with diabetes mellitus. Results from the ATLAS trial. Eur Heart J 2000; 21:-1967-1978
17. Lam PH, Dooley DJ, Fonarow GC, et al. Similar clinical benefits from below-target, and target dose enalapril in patients with heart failure in the SOLVD Treatment trial. Eur J Heart Fail. 5 October 2017 [Epub ahead of print]. https://doi .org/10.1002/ejhf.937
18. Witte KK, Drozd M, Walker AMN, et al. Mortality reduction associated with b-adrenoceptor inhibition in chronic heart failure is greater in patients with diabetes. Diabetes Care 2018; 41: 136-142
19. Olivier A, Pitt B, Girerd N, et al. Effect of eplerenone in patients with heart failure, and reduced ejection fraction: potential effect modification by abdominal obesity. Insight fromthe EMPHASIS-HF trial. Eur J Heart Fail 2017; 19: 1186-1197
20. Kristensen SL, Preiss D, Jhund PS, et al. PARADIGM-HF Investigators, and Committees. Risk related to pre-diabetes mellitus, and diabetes mellitus in heart failure with reduced ejection fraction: insights from Prospective Comparison of ARNI With ACEI to Determine Impact on Global Mortality andMorbidity in Heart Failure Trial. Circ Heart Fail 2016; 9: e002560
21. Tsujimoto T, Sugiyama T, Shapiro MF, Noda M, Kajio H. Risk of cardiovascular events in patients with diabetes mellitus on b-blockers. Hypertension 2017; 70: 103-110
22. Haas SJ, Vos T, Gilbert RE, Krum H. Are betablockers as efficacious in patients with diabetes mellitus as in patients without diabetes mellitus who have chronic heart failure? A meta-analysis of largescale clinical trials. Am Heart J 2003; 146: 848-853
23. Krum H, Roecker EB, Mohacsi P, et al. Carvedilol Prospective Randomized Cumulative Survival (COPERNICUS) Study Group. Effects of initiating carvedilol in patients with severe chronic heart failure: results from the COPERNICUS Study. JAMA 2003; 289: 712-718
24. Pitt B, Pfeffer MA, Assmann SF, et al. TOPCAT Investigators. Spironolactone for heart failure with preserved ejection fraction. N Engl J Med 2014; 370: 1383-1392
25. Obokata M, Reddy YNV, Pislaru SV, Melenovsky V, Borlaug BA. Evidence supporting the existence of a distinct obese phenotype of heart failure with preserved ejection fraction. Circulation 2017; 136: 6-19